GLP-1 receptor
also: GLP-1R, Glucagon-like peptide-1 receptor, GLP1R
Glucagon-like peptide-1 receptor, a class B GPCR mediating incretin-driven insulin secretion, appetite suppression, and gastric emptying delay.
The GLP-1 receptor (GLP-1R) is a class B G-protein-coupled receptor expressed on pancreatic beta cells, the central nervous system, heart, kidney, and gastrointestinal tract. Its endogenous ligand, Glucagon-like peptide-1 (GLP-1), is a 30-amino-acid incretin hormone secreted by intestinal L-cells in response to nutrient ingestion, and GLP-1R activation drives insulin secretion in a glucose-dependent manner while simultaneously suppressing glucagon release and slowing gastric emptying.
Why it matters in peptide research
The GLP-1 receptor has become one of the most therapeutically important targets in modern medicine following the clinical success of receptor agonists in treating type 2 diabetes and obesity. Its glucose-dependent mechanism of insulin stimulation is a critical safety feature: unlike sulfonylureas, GLP-1R agonists only amplify insulin secretion when blood glucose is elevated, dramatically reducing hypoglycemia risk.
Central GLP-1R signaling in the hypothalamus and brainstem reduces appetite and food intake by promoting satiety signaling and dampening reward-driven eating. This central component, combined with peripheral slowing of gastric emptying, produces the sustained caloric restriction that underlies the significant body weight reductions observed with pharmacological GLP-1R agonism. Understanding this dual peripheral-central action is essential for interpreting the clinical and research profiles of GLP-1R-targeting peptides.
Beyond metabolic effects, GLP-1R activation has demonstrated cardioprotective, neuroprotective, and anti-inflammatory properties in preclinical models, opening research avenues beyond diabetes and obesity into areas such as NASH, Alzheimer's disease, and heart failure.
Peptides that act on this
- Tirzepatide — dual GLP-1R/GIP receptor agonist; superior weight loss and glycemic control compared to GLP-1R mono-agonism; approved for type 2 diabetes and obesity.
- Retatrutide — triple agonist (GLP-1R, GIP receptor, glucagon receptor); early-phase data show the most pronounced weight loss of any peptide in this class to date.
- Semaglutide — highly potent selective GLP-1R agonist (Ozempic/Wegovy); the dominant clinical benchmark.
- Liraglutide — earlier-generation GLP-1R agonist; daily injection required.
Common misconceptions
A prevalent misconception is that GLP-1 receptor agonists are simple "appetite suppressants." Their mechanism is more nuanced: insulin potentiation, glucagon inhibition, gastric emptying delay, central satiety signaling, and direct organ-protective effects all contribute simultaneously. This complexity is why side-effect profiles (particularly nausea and gastrointestinal motility changes) are mechanistically predictable, and titration strategies that ramp dose slowly are the standard clinical approach.
Related on this site
Related glossary entries
GIP receptor
Glucose-dependent insulinotropic polypeptide receptor, an incretin GPCR on beta cells and adipocytes that enhances insulin secretion and modulates fat storage.
MC4R (Melanocortin-4 receptor)
Melanocortin-4 receptor, a hypothalamic GPCR controlling energy balance, sexual function, and autonomic tone; the primary target of PT-141 for sexual arousal.